---
title: "細胞動力公司董事 Muna Bhanji 報告了普通股的出售"
description: "細胞動力董事 Muna Bhanji 報告處置普通股。細胞動力公司董事 Muna Bhanji 報告了對該公司普通股的處置。完整的文件可以通過以下鏈接訪問"
type: "news"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/240461598.md"
published_at: "2025-05-15T22:52:10.000Z"
---

# 細胞動力公司董事 Muna Bhanji 報告了普通股的出售

> 細胞動力董事 Muna Bhanji 報告處置普通股。細胞動力公司董事 Muna Bhanji 報告了對該公司普通股的處置。完整的文件可以通過以下鏈接訪問

細胞動力董事 Muna Bhanji 報告處置普通股

細胞動力公司董事 Muna Bhanji 報告了對公司普通股的處置。完整的文件可以通過以下鏈接訪問。

### Related Stocks

- [CYTK.US - 細胞動力](https://longbridge.com/zh-HK/quote/CYTK.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Cytokinetics Reports Aficamten Outperforms Metoprolol in HCM Exercise Capacity Trial | Cytokinetics Incorporated announced new data from the MAPLE-HCM clinical trial, which showed that aficamten outperformed | [Link](https://longbridge.com/zh-HK/news/265150290.md) |
| Cardiac muscle therapeutics firm Cytokinetics Q3 net loss widens | Cytokinetics reported a Q3 net loss of $306.2 million, attributed to debt conversion expenses, despite a revenue increas | [Link](https://longbridge.com/zh-HK/news/264497991.md) |
| Pomerantz LLP Issues Reminder to Shareholders in Cytokinetics, Incorporate of Class Action Filing – CYTK | Pomerantz LLP has announced a class action lawsuit against Cytokinetics, Inc. for alleged securities fraud and unlawful  | [Link](https://longbridge.com/zh-HK/news/265405800.md) |
| 03:13 ET
			
			
				CYTK Investors Have Opportunity to Lead Cytokinetics, Incorporated Securities Fraud Lawsuit with the Schall Law Firm | The Schall Law Firm is reminding investors of a class action lawsuit against Cytokinetics, Incorporated (NASDAQ: CYTK) f | [Link](https://longbridge.com/zh-HK/news/265287432.md) |
| Class Action Reminder from Pomerantz LLP for Investors of Cytokinetics, Incorporate – CYTK | Pomerantz LLP has filed a class action lawsuit against Cytokinetics, Inc. for alleged securities fraud. Investors are en | [Link](https://longbridge.com/zh-HK/news/265187854.md) |

---

> **免責聲明**：本文內容僅供參考，不構成任何投資建議。
